Novo Nordisk to launch Ozempic for type 2 diabetes in US

Novo Nordisk is set to launch Ozempic, its oral GLP-1 receptor agonist pill for adults with type 2 diabetes, in the US. Ozempic oral pill will be produced entirely in the US and distributed through more than 70,000 pharmacies in the US. Ozempic pill is an oral GLP-1 medicine approved to reduce cardiovascular risk in adults with type 2 diabetes. Credit: Novo Nordisk/PRNewswire. Novo Nordisk is set to launch Ozempic, its oral glucagon-like peptide-1 (GLP-1) receptor agonist pill for adults with type 2 diabetes, in the US. The Ozempic oral pill, approved by the Food and Drug Administration (FDA), offers…

Source: Pharmaceutical Technology